MADEDDU, Denise
 Distribuzione geografica
Continente #
NA - Nord America 3.498
AS - Asia 2.685
EU - Europa 2.203
SA - Sud America 322
Continente sconosciuto - Info sul continente non disponibili 137
AF - Africa 111
OC - Oceania 6
Totale 8.962
Nazione #
US - Stati Uniti d'America 3.398
SG - Singapore 853
CN - Cina 807
IT - Italia 536
VN - Vietnam 426
SE - Svezia 362
IE - Irlanda 354
BR - Brasile 249
DE - Germania 219
FI - Finlandia 215
HK - Hong Kong 190
FR - Francia 124
BD - Bangladesh 104
ZA - Sudafrica 78
TR - Turchia 77
GB - Regno Unito 66
NL - Olanda 66
IN - India 65
CA - Canada 57
AT - Austria 56
UA - Ucraina 41
BE - Belgio 40
MX - Messico 29
CZ - Repubblica Ceca 28
IQ - Iraq 26
AR - Argentina 24
JP - Giappone 23
RU - Federazione Russa 22
PL - Polonia 21
EC - Ecuador 16
PK - Pakistan 15
PH - Filippine 14
LT - Lituania 13
CO - Colombia 11
ID - Indonesia 11
CI - Costa d'Avorio 10
TH - Thailandia 10
MA - Marocco 9
VE - Venezuela 9
ES - Italia 8
JO - Giordania 8
RO - Romania 8
UZ - Uzbekistan 8
KR - Corea 7
AU - Australia 6
AZ - Azerbaigian 5
CH - Svizzera 5
JM - Giamaica 5
OM - Oman 5
TN - Tunisia 5
TW - Taiwan 5
AL - Albania 4
NP - Nepal 4
UY - Uruguay 4
KE - Kenya 3
MY - Malesia 3
PY - Paraguay 3
SA - Arabia Saudita 3
AE - Emirati Arabi Uniti 2
BB - Barbados 2
BO - Bolivia 2
CL - Cile 2
EG - Egitto 2
EU - Europa 2
GR - Grecia 2
HN - Honduras 2
HU - Ungheria 2
IL - Israele 2
IR - Iran 2
KH - Cambogia 2
PE - Perù 2
RS - Serbia 2
SY - Repubblica araba siriana 2
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BT - Bhutan 1
BW - Botswana 1
BY - Bielorussia 1
BZ - Belize 1
CR - Costa Rica 1
GE - Georgia 1
GH - Ghana 1
HR - Croazia 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
MK - Macedonia 1
MT - Malta 1
NI - Nicaragua 1
PR - Porto Rico 1
PS - Palestinian Territory 1
PT - Portogallo 1
SC - Seychelles 1
SI - Slovenia 1
SN - Senegal 1
TT - Trinidad e Tobago 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 8.828
Città #
Singapore 487
Ashburn 428
Chandler 395
Dublin 354
San Jose 293
Dallas 209
Ann Arbor 186
Parma 183
Hong Kong 178
Santa Clara 178
Beijing 165
Ho Chi Minh City 126
Boardman 120
Dearborn 113
New York 109
Hanoi 86
Shanghai 82
Los Angeles 79
Munich 76
Nanjing 76
Johannesburg 75
Council Bluffs 62
Izmir 58
Padova 57
Lauterbourg 55
Princeton 54
Bremen 49
Vienna 49
Wilmington 45
Helsinki 43
Jacksonville 43
Brussels 40
Buffalo 35
Nanchang 31
Jinan 28
São Paulo 27
Haiphong 25
Milan 25
Hebei 24
Columbus 21
Seattle 21
Toronto 21
Brooklyn 19
London 18
San Mateo 18
Frankfurt am Main 17
Hefei 17
Pune 17
Shenyang 17
Tokyo 17
Des Moines 16
Guangzhou 16
Jiaxing 16
Kunming 16
Rio Saliceto 16
Turku 16
Warsaw 16
Rome 15
Changsha 14
Da Nang 14
Fremont 13
Houston 13
Norwalk 13
Atlanta 12
Brno 12
Montreal 12
Moscow 12
Zhengzhou 12
Baghdad 11
Denver 11
Hải Dương 11
Stockholm 11
The Dalles 11
Tianjin 11
Abidjan 10
Modena 10
Nuremberg 10
Redmond 10
Tulsa 10
Boston 9
Chennai 9
Hangzhou 9
Mexico City 9
Phoenix 9
Woodbridge 9
Olomouc 8
Rio de Janeiro 8
Amman 7
Can Tho 7
Charlotte 7
Falkenstein 7
Jakarta 7
Curitiba 6
Falls Church 6
Guayaquil 6
Haikou 6
Kocaeli 6
Lahore 6
Marseille 6
Orem 6
Totale 5.474
Nome #
Parenchymal and Stromal Cells Contribute to Pro-Inflammatory Myocardial Environment at Early Stages of Diabetes: Protective Role of Resveratrol 290
Cardioprotection by Targeting the Pool of Resident and Extracardiac Progenitors 220
Validation of a radiomic approach to decipher NSCLC immune microenvironment in surgically resected patients 214
L’autofagia coinvolge i cardiomiociti e le cellule progenitrici nella cardiomiopatia indotta da imatinib mesilato 205
Low PD-1 expression in Cytotoxic CD8+ Tumor infiltrating Lymphocytes Confers an Immune Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value 205
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 202
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 199
Imatinib mesylate-induced cardiomyopathy involves resident cardiac progenitors 198
INTEGRATION OF TISSUE PD-1/PD-L1 IMMUNE CHECKPOINT WITH COMPUTED TOMOGRAPHY (CT) BASED TEXTURE ANALYSIS EXHIBITS HIGH PROGNOSTIC IMPACE ON SURGICALLY RESECTED NON SMALL CELL LUNG CANCER (NSCLC) 195
Blood and lymphatic vessels contribute to the impact of the immune microenvironment on clinical outcome in non-small-cell lung cancer 193
Lymphangiogenesis in genetically determined hypertrophic obstructive cardiomyopathy 189
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 185
MESENCHYMAL STROMAL CELLS ISOLATED FROM DEFINED NSCLC CONTEXTURES REPRODUCE THE IMMUNE SIGNATURE OF THE PARENTAL MICROENVIRONMENT 184
Bone Marrow Remodelling and Topographic Redistribution of CD34 Positive Progenitors Characterize the Progression of Myelodysplastic Syndromes and Their Evolution to AML 184
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 181
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC 180
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 175
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 174
Dataset on the identification of a prognostic radio-immune signature in surgically resected Non Small Cell Lung Cancer 174
Cancer treatment-induced cardiotoxicity: a cardiac stem cell disease? 171
In Vitro Biological and Functional Properties of Human Endothelial Cells from Different Sources Exposed to Different Beta-Blockers 170
BLOOD AND LYMPHATIC VESSELS CONSTITUTE AN ESSENTIAL COMPONENT OF THE IMMUNE MICROENVIRONMENT AND ITS IMPACT ON NON SMALL CELL LUNG CANCER (NSCLC) CLINICAL OUTCOME 169
Integrated MRI–Immune–Genomic Features Enclose a Risk Stratification Model in Patients Affected by Glioblastoma 163
Lung mesenchymal cells function as an inductive microenvironment for human lung cancer propagating cells† 163
Assessment of Cardiac Patches Suitability for Tissue Engineering 160
Isolation and characterization of human lung lymphatic endothelial cells 159
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 159
Dissecting the cellular mechanisms of cardiotoxicity by anthracycline and tyrosine kinase inhibitors 158
Potential involvement of cardiac and bone marrow vascular progenitors in imatinib induced cardiovascular toxicity 156
Structural and Functional Characterization of the Hemolymphangiogenic Microenvironment in Lung Cancer 155
Clinico-Immunological Profile of a 67-Year-Old Woman Affected by HER2-Positive Breast Cancer and Autoimmune Dermatomyositis 155
Integrated CT imaging and tissue immune features disclose a radio-immune signature with high prognostic impact on surgically resected NSCLC 153
Spatial architecture of tumour-infiltrating lymphocytes as a prognostic parameter in resected non-small-cell lung cancer 153
Notch Activation Modulates Bevacizumab Activity by CD44 Positive Cancer Stem Cells in Advanced Colon Cancer 150
Identification and tumorigenic role of Mesenchymal Stem Cells from human lung cancer 147
Resident cardiac stem cells. 146
Differential Pattern of Myocardial Remodelling in Genetically Determined and Load- Dependent Hypertrophy in Humans 144
Stem cells and myocardial regeneration 143
Tyrosine kinase cardiotoxicity: ultrastructural analysis of imatinib mesylate induced cardiomyopathy 142
Development of biomimetic alginate/gelatin/elastin sponges with recognition properties toward bioactive peptides for cardiac tissue engineering 137
Differential Tumorigenic Properties of Mesenchymal Cells From Neoplastic and Non-Neoplastic Human Lung in NSCLC 132
Biomimetic poly(glycerol sebacate) (PGS) membranes for cardiac patch application 131
YES1 and MYC Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs 131
SURGICAL SAMPLING IS AN EMERGING ISSUE IN THE ASSESSMENT OF THE IMMUNE CONTEXTURE IN NON SMALL CELL LUNG CANCER (NSCLC) 127
IMPACT OF THE TISSUE DISTRIBUTION OF SUBPOPULATIONS OF TILS AND PD-L1 EXPRESSION ON THE CLINICAL OUTCOME OF NSCLC 125
Favorable clinical outcome and response to immunotherapy share a common PD-L1/PD-1 based NSCLC immune contexture 124
IGF-1 loaded injectable microspheres for potential repair of the infarcted myocardium 117
Low vagally-mediated heart rate variability and increased susceptibility to ventricular arrhythmias in rats bred for high anxiety. 114
Advanced CT imaging features reflect distinct tissue immune profiles and exhibit high prognostic impact on NSCLC 113
Correction: A versatile bioreactor for dynamic suspension cell culture. Application to the culture of cancer cell spheroids 112
Divergent PD-1 expression in tissue and circulating CD8 lymphocytes defines an immune profile predictive of the response to nivolumab in advanced NSCLC 109
Inhibition of Human Malignant Pleural Mesothelioma Growth by Mesenchymal Stromal Cells 108
LUNG MESENCHYMAL STEM CELLS FUNCTION AS THE INDUCTIVE MICROENVIRONMENT FOR HUMAN LUNG CANCER PROPAGATING CELLS 104
Influence of injectable microparticle size on cardiac progenitor cell response 102
Reinforced alginate/gelatin sponges functionalized by avidin/biotin-binding strategy: a novel cardiac patch 89
In vitro suspension bioreactor-based platform for culturing tumor cell clusters 85
Thermoreversible injectable polyurethane hydrogels: future challenges for biomedical applications 72
Transcriptomic analysis reveals lipid metabolism and macrophage involvement associated with nintedanib treatment in a rat bleomycin model 61
Structural and functional characterization of vascular phenotype in lung cancer 6
Totale 8.962
Categoria #
all - tutte 31.149
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.149


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022256 0 11 9 14 4 10 39 21 12 21 11 104
2022/20231.524 160 186 102 121 160 156 37 81 428 10 69 14
2023/2024566 22 41 8 16 50 152 51 24 17 46 66 73
2024/20251.418 29 71 102 114 164 125 82 71 134 121 139 266
2025/20263.339 334 256 366 295 447 176 342 113 451 282 136 141
2026/202798 64 34 0 0 0 0 0 0 0 0 0 0
Totale 8.962